Safety Communication

Dear Healtcare Professionals,

 

Related Dengvaxia vaccine safety issue (dengue vaccine) published in the media regarding the suspension of use of the Dengvaxia Vaccine (dengue vaccine) in immunization programs in the Philippines, the results of an explorative study are :

- an increased risk of hospitalization and severe dengue in individuals with negative serotesting or have not previously been infected with dengue and;

- the benefits of good protection on individuals with positive serotesting or previously infected with dengue

NADFC has published an explanation of the dengue vaccine safety issue on December 12, 2017 as the following links:

 

http://www.pom.go.id/new/view/more/klarifikasi/72/PENJELASAN-BADAN-POM-RI--TERKAIT-ISU-KEAMANAN-VAKSIN-DENGUE--DEMAM-BERDARAH-.html

 

Regards,

National Pharmacovigilance Center


Download :
Poll
How do you think the content and appearance of this website?




logo dsras Email Rapid Alert System

Selamat email anda telah berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia.

 

logo dsras Email Rapid Alert System

Anda ingin berhenti berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia?